Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-clear Study: Libevitug in Chronic Hepatitis Delta Virus Infection
NCT07499544Phase 3Recruiting
- Sponsor
- Huahui Health
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of Libevitug in chronic hepatitis D (3 arms), sponsored by Huahui Health. Primary endpoint: Proportion of participants with HDV RNA below LLOQ with TND or a decrease of >= 2 log10 from baseline, and ALT normalization at 48 weeks. Started Apr 2026; status: recruiting.
02
Drugs
Libevitug
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT07499544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499544.